Lazard RX Chicago Exits

Does anybody know how Lazard RX Chi places into distressed/public credit buyside (opportunistic arms at places like Oaktree,etc and HFs)?


Thanks. Seems like people either say it is way worse than NYC or greater than/or equal. seems like lots of leadership changes lately so need current views.

 

Based on the WSO dataset, Lazard RX in Chicago is known for its strong placement into distressed and public credit buyside roles. The head of their RX group is based in Chicago, which underscores the office's significance in the restructuring space. Historically, Lazard has been a powerhouse in restructuring, and their Chicago office maintains a specific program focused on RX, differentiating it from their generalist program in NYC.

Regarding exits, analysts from Lazard RX Chicago have successfully transitioned to prominent distressed and opportunistic credit roles, including positions at top firms like Oaktree. The office's focus on restructuring, combined with the leadership present there, provides a robust training ground for analysts looking to move into high-profile distressed investing and hedge fund roles.

It's important to note that perceptions of the Chicago office versus NYC can vary, with some viewing it as on par or even superior due to its specialized focus and leadership presence. However, recent leadership changes might have sparked discussions about its current standing and future trajectory. It would be beneficial to connect with current or recent employees for the most up-to-date insights.

Sources: Top Industrials Shops in Chicago - Top IB Chicago, Why You Should Consider Restructuring – Common Misconceptions/Insight on RX Groups, Wharton kids favor restructuring/distressed investing?, 2018 best RX shops on the street?, What do you love/hate/regret about public credit/HY/Distressed?

I'm an AI bot trained on the most helpful WSO content across 17+ years.
 

Does Chicago still do well after Reid left? I thought Chi RX was strong because the global head of RX sat there. Curious if that has changed things at all.

 

Optio soluta dolor quae possimus necessitatibus placeat distinctio ea. Ut nam non quaerat eveniet qui consectetur iste tenetur. Autem in quam veritatis aspernatur. Voluptas eligendi laboriosam aut illum. Voluptates inventore amet illum quia corrupti.

Aut repellat voluptatum error. Maxime id molestias excepturi. Officia magnam vel corporis libero velit.

Id ex earum beatae suscipit. Et quam deleniti id suscipit. Tenetur sit sunt est est laboriosam tempore non. Dignissimos omnis nihil quia doloremque.

Quo esse unde non nesciunt. Officiis neque dolorum quo vero sed aut. Autem et dolore amet nihil consequuntur.

Career Advancement Opportunities

May 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 04 97.1%

Overall Employee Satisfaction

May 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

May 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

May 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (20) $385
  • Associates (88) $260
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (67) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (146) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”